MedTrace Logo

Schistosoma Haematobium Infections and Praziquantel

NCT01558336 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2013-01-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.

Conditions

  • Schistosomiasis

Interventions

DRUG

praziquantel

praziquantel 40 mg/kg oral tablets

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    collaborator INDUSTRY

  • University of Khartoum

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-08-31
Completion
2012-09-30

Countries

  • Sudan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01558336 on ClinicalTrials.gov